<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               2 DOSAGE AND ADMINISTRATION<BR>               <BR>                  Enter section text here<BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                        Letrozole tablets are taken orally without regard to meals (2): <BR>                        <BR>                           Recommended dose: 2.5 mg once daily (2.1) <BR>                           Patients with cirrhosis or severe hepatic impairment: 2.5 mg every other day <BR>(2.5, 5.3) <BR><BR>                        <BR>                        <BR><BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     2.1 Recommended Dose<BR>                     <BR>                        The recommended dose of letrozole tablets is one 2.5 mg tablet <BR>administered once a day, without regard to meals. <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     2.2 Use in Adjuvant Treatment of Early Breast Cancer<BR>                     <BR>                        <BR>                        <BR>                           In <BR>the adjuvant setting, the optimal duration of treatment with letrozole tablets <BR>is unknown. The planned duration of treatment in the study was 5 years with 73% <BR>of the patients having completed adjuvant therapy. Treatment should be <BR>discontinued at relapse [see Clinical Studies <BR>(14.1)]. <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     2.3 Use in Extended Adjuvant Treatment of Early Breast Cancer<BR>                     <BR>                        In the extended adjuvant setting, the optimal treatment duration with letrozole <BR>tablets is not known. The planned duration of treatment in the study was 5 <BR>years. In the final updated analysis, conducted at a median follow-up of 62 <BR>months, the median treatment duration was 60 months. Seventy-one percent of <BR>patients were treated for at least 3 years and 58% of patients completed least <BR>4.5 years of extended adjuvant treatment. The treatment should be discontinued <BR>at tumor relapse [see Clinical Studies <BR>(14.2)].<BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     2.4 Use in First and Second-Line Treatment of Advanced Breast Cancer<BR>                     <BR>                        In patients with advanced disease, treatment with letrozole <BR>tablets should continue until tumor progression is evident [see Clinical Studies <BR>(14.4, 14.5)]. <BR><BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     2.5 Use in Hepatic Impairment<BR>                     <BR>                        No dosage adjustment is recommended for patients with mild to <BR>moderate hepatic impairment, although letrozole blood concentrations were <BR>modestly increased in subjects with moderate hepatic impairment due to <BR>cirrhosis. The dose of letrozole in patients with cirrhosis and severe hepatic <BR>dysfunction should be reduced by 50% [see Warnings and <BR>Precautions (5.3)]. The recommended dose of letrozole tablets for <BR>such patients is 2.5 mg administered every other day. The effect of hepatic <BR>impairment on letrozole tablets exposure in noncirrhotic cancer patients with <BR>elevated bilirubin levels has not been determined. <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     2.6 Use in Renal Impairment<BR>                     <BR>                        No dosage adjustment is required for patients with renal impairment if <BR>creatinine clearance is â‰¥ 10 mL/min [see Clinical <BR>Pharmacology (12.3)]<BR>                        <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>